Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,553 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: IBD Clear all
Completed Early Phase 1 Interventional

Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases

NCT02925351
View directory record Official record
Conditions
Autoimmune Disease, Crohn Disease, Inflammatory Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Takayasu Arteritis
Interventions
Computed Tomography, Fluorine F 18 Clofarabine, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 22, 2026, 7:20 AM EDT
Recruiting Phase 3 Interventional

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

NCT05509777
View directory record Official record
Conditions
Crohn's Disease
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 17 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Hartford, Connecticut • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 7:20 AM EDT
Completed Not applicable Interventional

Education Intervention on Vaccination Adherence Among Inflammatory Bowel Disease (IBD) Patients

NCT04672161
View directory record Official record
Conditions
Crohn Disease (CD), Ulcerative Colitis (UC), Indeterminate Colitis
Interventions
Vaccine Education
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 22, 2026, 7:20 AM EDT
Completed Phase 3 Interventional Results available

Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

NCT03996369
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
16 Years to 80 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
62
States / cities
Dothan, Alabama • Mobile, Alabama • Sun City, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 22, 2026, 7:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects

NCT01802073
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Oral Vancomycin
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Year and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 22, 2026, 7:20 AM EDT
Terminated Phase 3 Interventional Results available

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

NCT01316939
View directory record Official record
Conditions
Crohn's Disease
Interventions
GSK1605786A, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
54
States / cities
Little Rock, Arizona • Tucson, Arizona • La Jolla, California + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Oct 22, 2026, 7:20 AM EDT
Not listed No phase listed Observational

Infliximab Proactive Drug Monitoring in the Pediatric IBD Population

NCT04921670
View directory record Official record
Conditions
Inflammatory Bone Disease
Interventions
Infliximab Assay
Diagnostic Test
Lead sponsor
Cares, Kristen, M.D.
Other
Eligibility
5 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 7:20 AM EDT
Completed Phase 3 Interventional Results available

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease

NCT00160706
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab Pegol (CDP870)
Biological
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 22, 2026, 7:20 AM EDT
Completed No phase listed Observational Results available

Assessment of Colonic Epithelial Integrity With Mucosal Impedance

NCT03165058
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
mucosal impedance (MI) testing
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 22, 2026, 7:20 AM EDT
Completed Not applicable Interventional

Addressing Disability Effectively With Psychosocial Telemedicine

NCT05635292
View directory record Official record
Conditions
Crohn Disease
Interventions
Tele-CBT
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 22, 2026, 7:20 AM EDT
Completed Not applicable Interventional

Care Coordination and Proactive Care to Improve Utilization of Resources and Reduce Expenditure in High Risk Inflammatory Bowel Disease (IBD) Patients

NCT04796571
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Proactive Symptom Monitoring and Care Coordination
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 90 Years
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Oct 22, 2026, 7:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Analyzing IBS to Identify Biomarkers and Microbiome Signatures

NCT02419963
View directory record Official record
Conditions
Diarrhoea Predominant Irritable Bowel Syndrome, IBS
Interventions
endoscopy for tissue biopsy, Blood Sample, Stool Sample
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 22, 2026, 7:20 AM EDT
Terminated Phase 4 Interventional Results available

Ultrasound Evaluation of Crohn's Disease

NCT03235180
View directory record Official record
Conditions
Crohn Disease
Interventions
Sulfur Hexafluoride, Ultrasound Elastography, Ultrasound Vascularity, Magnetic Resonance Enterography (MRE)
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 22, 2026, 7:20 AM EDT
Active, not recruiting No phase listed Observational

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

NCT00606346
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, Inflammatory Bowel Diseases
Interventions
Anti TNF therapy including infliximab, No Biologics
Biological · Drug
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
1 Month to 17 Years
Enrollment
4,970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2038
U.S. locations
58
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 7:20 AM EDT
Completed Phase 2 Interventional

Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo

NCT00739986
View directory record Official record
Conditions
Crohn's Disease
Interventions
Semapimod, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 22, 2026, 7:20 AM EDT
Completed Phase 3 Interventional Results available

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

NCT03518086
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mirikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
98
States / cities
Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 22, 2026, 7:20 AM EDT
Completed Phase 3 Interventional Results available

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

NCT01453946
View directory record Official record
Conditions
Crohn's Disease
Interventions
Entocort
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
5 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
7
States / cities
Atlanta, Georgia • Oak Lawn, Illinois • Newton, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 22, 2026, 7:20 AM EDT
Terminated Phase 1 Interventional

A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis

NCT05549323
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
PF-07054894, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Kissimmee, Florida • Tampa, Florida • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 22, 2026, 7:20 AM EDT
Active, not recruiting Phase 2 Interventional

Phase IIa Study Evaluating AZD7798 in Crohn's Disease

NCT06450197
View directory record Official record
Conditions
Moderate to Severe Crohn's Disease
Interventions
AZD7798, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Escondido, California • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 22, 2026, 7:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Malnutrition Associated With Complications After Ileostomy Reversal

NCT03909542
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ileostomy
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Not listed
Enrollment
359 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 22, 2026, 7:20 AM EDT
Withdrawn No phase listed Observational

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS

NCT04214470
View directory record Official record
Conditions
Irritable Bowel, Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea, Irritable Bowel Syndrome Mixed, Irritable Bowel Syndrome With Constipation, Irritable Bowel Syndrome Without Diarrhea, Irritable Bowel Syndrome Aggravated, Irritable Bowel Syndrome Characterized by Constipation, Irritable Bowel Syndrome Characterised by Alternating Bowel Habit
Interventions
No intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 22, 2026, 7:20 AM EDT
Completed No phase listed Observational

Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab

NCT03056924
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Oct 22, 2026, 7:20 AM EDT
Completed Phase 1Phase 2 Interventional

Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS)

NCT01890837
View directory record Official record
Conditions
Irritable Bowel Syndrome, Digestive System Diseases, Gastrointestinal Diseases, Intestinal Diseases, Abdominal Pain
Interventions
Daikenchuto (TU-100), Placebo
Drug
Lead sponsor
Tsumura USA
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Oct 22, 2026, 7:20 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Capsule Microbiota Sampling in IBS/Functional Gastrointestinal Disease

NCT06215222
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome, Healthy, Functional Bloating, Functional Gastrointestinal Disorders
Interventions
Microbiota Sampling
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Oct 22, 2026, 7:20 AM EDT